PartnershipUpdated on 1 September 2025
Partnership opportunities in advanced targeted therapies for cancer
About
Protyon is seeking partnership opportunities with organizations developing advanced targeted therapies. We are especially interested in exploring new avenues and cancer drivers beyond non-small cell lung cancer.
We can de-risk development pipelines by assessing novel mutations, supporting drug efficacy evaluation, and enhancing cohort selection to increase clinical trial success. With particular expertise in tyrosine kinase inhibitors (EFGR, BRAF, ALK), we help partners optimize patient selection and minimize unsuccessful treatments.
Organisation
Similar opportunities
Project cooperation
Precision oncology for advanced targeted therapies
- Early
- Research
- Financing
Rositsa Jordanova
CEO and founder at Protyon
Groningen, Netherlands
Service
In Silico Solutions to De-risk Drug Development and Empower Precision Medicine
- Consulting
- Development
- Innovative therapies - Precision medicine
- Innovative human-based test models - In silico human models
- Development stages and support fuctions - Contract research (CRO / CRMO)
- Development stages and support fuctions - Clinical research and development
- Development stages and support fuctions - Pre-clinical research and development
Rositsa Jordanova
CEO and founder at Protyon
Groningen, Netherlands
Investment
Investment opportunity for Pharma and Healthcare Inverstors
- Startup
- Expansion
- Possible Exit
- Innovative therapies
- Growth and Establishment
- Development stages and support fuctions
Rositsa Jordanova
CEO and founder at Protyon
Groningen, Netherlands